← Back to Search

Antibody-drug conjugate

CAB-AXL-ADC + PD-1 Inhibitor for Lung Cancer

Phase 2
Recruiting
Research Sponsored by BioAtla, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate renal function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective for patients with non-small cell lung cancer.

Who is the study for?
Adults over 18 with non-small cell lung cancer (NSCLC) who have measurable disease, are in good physical condition (ECOG status of 0 or 1), and expected to live at least three months. They must have proper blood, kidney, and liver function. Those with severe heart issues, prior specific cancer treatments, recent major surgery, uncontrolled brain metastasis, certain allergies or infections like HIV/hepatitis are excluded.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of a new drug called CAB-AXL-ADC for NSCLC patients. It's being compared against PD-1 inhibitors which are a type of immunotherapy that helps the immune system fight cancer cells.See study design
What are the potential side effects?
Possible side effects include allergic reactions related to monoclonal antibody therapy; however specific side effects for CAB-AXL-ADC aren't listed but may be similar to other chemotherapy drugs such as fatigue, nausea, low blood counts increasing infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidneys are working well.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My liver is working well.
Select...
I am 18 years old or older.
Select...
My blood counts are within a healthy range.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Confirmed Objective Response Rate (ORR) per RECIST v1.1
Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5
Secondary outcome measures
Best overall response (BOR)
Disease control rate (DCR)
Duration of response (DOR)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: CAB-AXL-ADC (BA3011)+PD-1 inhibitorExperimental Treatment2 Interventions
CAB-AXL-ADC (BA3011) with PD-1 inhibitor
Group II: CAB-AXL-ADC (BA3011)Experimental Treatment1 Intervention
CAB-AXL-ADC (BA3011) alone

Find a Location

Who is running the clinical trial?

BioAtla, Inc.Lead Sponsor
6 Previous Clinical Trials
1,168 Total Patients Enrolled

Media Library

CAB-AXL-ADC (Antibody-drug conjugate) Clinical Trial Eligibility Overview. Trial Name: NCT04681131 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: CAB-AXL-ADC (BA3011)+PD-1 inhibitor, CAB-AXL-ADC (BA3011)
Non-Small Cell Lung Cancer Clinical Trial 2023: CAB-AXL-ADC Highlights & Side Effects. Trial Name: NCT04681131 — Phase 2
CAB-AXL-ADC (Antibody-drug conjugate) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04681131 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~74 spots leftby Aug 2025